Low doses of antianxiety drugs rebalance the autistic brain

March 19, 2014

New research in mice suggests that autism is characterized by reduced activity of inhibitory neurons and increased activity of excitatory neurons in the brain, but balance can be restored with low doses of a well-known class of drugs currently used in much higher doses to treat anxiety and epileptic seizures. The findings, which are reported in the March 19th issue of the Cell Press journal Neuron, point to a new therapeutic approach to managing autism.

"These are very exciting results because they suggest that existing drugs—called —might be useful in treatment of the core deficits in autism," says senior author Dr. William Catterall of the University of Washington, in Seattle.

In addition to finding that mice with autistic characteristics had an imbalance between the inhibitory and excitatory neurons in their brains, Dr. Catterall and his team found that reducing the effectiveness of in normal mice also induced some autism-related deficits in social behavior. Classical benzodiazepine drugs had the opposite effect, increasing the activity of inhibitory neurons and diminishing autistic behaviors.

"Our results provide strong evidence that increasing inhibitory neurotransmission is an effective approach to improvement of social interactions, repetitive behaviors, and cognitive deficits in a well-established animal model of autism, having some similar behavioral features as human ," says Dr. Catterall.

Therapeutic approaches to treat autistic traits in animal studies or in have primarily focused on reducing the activity of excitatory neurons, with only modest success to date. The results reported by Dr. Catterall and his colleagues suggest that augmenting the activity of opposing, inhibitory neurons could be an alternative strategy.

Clinical trials of classical benzodiazepines and next-generation drugs that have a similar mechanism of action are now needed to determine whether the researchers' findings in mice are relevant to humans. Astra-Zeneca and the National Institutes of Health have initiated one such trial.

Explore further: Brain cell activity imbalance may account for seizure susceptibility in Angelman syndrome

More information: Neuron, Han et al.: "Enhancement of Inhibitory Neurotransmission by GABAA Receptors Having 2,3-Subunits Ameliorates Behavioral Deficits in a Mouse Model of Autism." dx.doi.org/10.1016/j.neuron.2014.01.016

Related Stories

Recommended for you

Drug used to treat cancer appears to sharpen memory

October 2, 2015

Can you imagine a drug that would make it easier to learn a language, sharpen your memory and help those with dementia and Alzheimer's disease by rewiring the brain and keeping neurons alive?

Brain chemical aids tic control in Tourette Syndrome

October 1, 2015

A chemical in the brain could potentially be harnessed to help young people with Tourette Syndrome (TS) to overcome the physical and vocal tics associated with the neurological disorder, say researchers.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.